 Levodopa
"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
| Descriptor ID |
D007980
|
| MeSH Number(s) |
D02.092.311.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500
|
| Concept/Terms |
Levodopa- Levodopa
- L-Dopa
- L Dopa
- 3-Hydroxy-L-tyrosine
- 3 Hydroxy L tyrosine
- L-3,4-Dihydroxyphenylalanine
- L 3,4 Dihydroxyphenylalanine
Dopar- Dopar
- Roberts Brand of Levodopa
Dopaflex- Dopaflex
- Medphano Brand of Levodopa
|
Below are MeSH descriptors whose meaning is more general than "Levodopa".
Below are MeSH descriptors whose meaning is more specific than "Levodopa".
This graph shows the total number of publications written about "Levodopa" by people in UAMS Profiles by year, and whether "Levodopa" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 | | 2021 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2019 | 2 | 2 | 4 | | 2016 | 1 | 1 | 2 | | 2015 | 0 | 1 | 1 | | 2014 | 1 | 2 | 3 | | 2013 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2003 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 1992 | 0 | 1 | 1 | | 1990 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Levodopa" by people in Profiles over the past ten years.
-
Landes RD, Glover A, Pillai L, Doerhoff S, Virmani T. Levodopa ONOFF-state freezing of gait: Defining the gait and non-motor phenotype. PLoS One. 2022; 17(6):e0269227.
-
Syeda HB, Glover A, Pillai L, Kemp AS, Spencer H, Lotia M, Larson-Prior LJ, Virmani T. Amplitude setting and dopamine response of finger tapping and gait are related in Parkinson's disease. Sci Rep. 2022 03 09; 12(1):4180.
-
Baudendistel ST, Schmitt AC, Roemmich RT, Harrison IL, Hass CJ. Levodopa facilitates improvements in gait kinetics at the hip, not the ankle, in individuals with Parkinson's disease. J Biomech. 2021 05 24; 121:110366.
-
Cisler JM, Privratsky AA, Sartin-Tarm A, Sellnow K, Ross M, Weaver S, Hahn E, Herringa RJ, James GA, Kilts CD. L-DOPA and consolidation of fear extinction learning among women with posttraumatic stress disorder. Transl Psychiatry. 2020 08 15; 10(1):287.
-
Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 02; 71:4-10.
-
Paul SS, Dibble LE, Olivier GN, Walter C, Duff K, Schaefer SY. Dopamine replacement improves motor learning of an upper extremity task in people with Parkinson disease. Behav Brain Res. 2020 01 13; 377:112213.
-
Gupta HV, Lyons KE, Pahwa R. Old Drugs, New Delivery Systems in Parkinson's Disease. Drugs Aging. 2019 09; 36(9):807-821.
-
Olivier GN, Paul SS, Lohse KR, Walter CS, Schaefer SY, Dibble LE. Predicting Motor Sequence Learning in People With Parkinson Disease. J Neurol Phys Ther. 2019 01; 43(1):33-41.
-
Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 05; 86(14 Suppl 1):S13-24.
-
Lotia M, Jankovic J. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016; 17(7):895-909.
-
Weiss D, Klotz R, Govindan RB, Scholten M, Naros G, Ramos-Murguialday A, Bunjes F, Meisner C, Plewnia C, Krüger R, Gharabaghi A. Subthalamic stimulation modulates cortical motor network activity and synchronization in Parkinson's disease. Brain. 2015 Mar; 138(Pt 3):679-93.
-
Fang JY, Pérez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL. Parkinson's disease severity and use of dopaminergic medications. Parkinsonism Relat Disord. 2015 Mar; 21(3):297-9.
-
Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. PLoS One. 2014; 9(12):e112287.
-
Zhang L, Balan G, Barreiro G, Boscoe BP, Chenard LK, Cianfrogna J, Claffey MM, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Fonseca KR, Galatsis P, Grimwood S, Lazzaro JT, Mancuso JY, Miller EL, Reese MR, Rogers BN, Sakurada I, Skaddan M, Smith DL, Stepan AF, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Wright AS, Zaleska MM, Zasadny K, Shaffer CL. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. J Med Chem. 2014 Feb 13; 57(3):861-77.
-
Virmani T, Thenganatt MA, Goldman JS, Kubisch C, Greene PE, Alcalay RN. Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia. Parkinsonism Relat Disord. 2014 Feb; 20(2):245-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|